Based on the average R&D costs in producing a drug, the first 10 medications selected will still garner big revenue.
The prescription drug provisions of the Inflation Reduction Act have generated a deluge of doomsday predictions from the pharmaceutical industry regarding drug innovation. Big Pharma has focused on the provision requiring the federal government to negotiate prices for selected eligible drugs covered under Medicare Part B and Part D with the highest total spending, beginning in 2026. On Tuesday, we got the list of the first 10 medications that will be up for negotiation.
